Alliance for Cell Therapy Now

“Other office expenses $12.00”

“Information technology $300.00”

“Other $235.00”

“Compliance consulting $529.00”

“Accounts receivable, net. Beginning:$0.00 Ending: $2000.00”

“Accounts payable and accrued expenses. Beginning:$11302.00 Ending: $1103.00”

“Advance the availability of safe and effective regenerative”

“cell therapies for patients in need.”

“1. In support of its goal to advance therapies to support patients in”

“need, the organization convened an advisory group comprised of”

“scientists, researchers, clinical experts, and patients to guide the”

“development of policy actions needed to advance the field.”

“2. In support of its goal to advance therapies to support patients in”

“need through education and advocacy, the organization developed white”

“papers, briefs, and other communications materials raise awareness of”

“the current state of the field, barriers to progress, and policy”

“actions needed.”

“3. In support of its goal to advance therapies to support patients in”

“need,the organization assessed the federal government's progress”

“against legislative requirements and other federal policies.”

“4. In support of its goal to advance therapies to support patients in”

“need, the organization successfully advocated for public policy to”

“encourage greater investment in clinical trials, the characterization,”

“optimization and scaling of manufacturing, and collaborative”

“evidence development and transparency related to such therapies.”

“5. In support of its goal to advance therapies to support patients in”

“need, the organization developed and advocated for a policy proposal”

“for modernizing the regulatory framework for cell therapies.”

“6. In support of its goal to advance therapies to support patients in”

“need, the organization advocated for funding for a center for”

“innovation in cell and gene therapy to support academic medical”

“centers and small biotechs with early stage clinical trials, manufacturing”

“and navigating regulatory evaluation and approval of cell therapies.”